establishment and validation of the prediction model of avastin plus chemotherapy as first line treatment in simultaneous ras mutant unresectable CRLM patients
Ras mutant unresectable CRLM patients with primary tumor resection followed by avastin in combination with chemotherapy were included in this study. The tumor response was assessed by local MDT group. Based on tumor response, 58 CRLM patients were classified into two groups (CR+PR vs SD+PD). Primary samples of the two group patients will be sequenced by mass spectrum. After MS sequencing, a prediction model will be estimated. Another 58 CRLM patients will be inclued for validation of the prediction model.
Study Type
OBSERVATIONAL
Enrollment
116
response rate
response rate will be assessed by local MDT every two months
Time frame: 6 months
overall survival
overall survival will be assessed by researchers every two months during treatment, and telephone follow-up every three month after treatment
Time frame: 3 years
progression free survival
progression free survival will be assessed by local MDT every two months during treatment, and telephone follow-up every three month after treatment
Time frame: 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.